<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02848742</url>
  </required_header>
  <id_info>
    <org_study_id>R2-16-001</org_study_id>
    <nct_id>NCT02848742</nct_id>
  </id_info>
  <brief_title>Dermal Cryotherapy for Treatment of Pigmented Lesions</brief_title>
  <official_title>Evaluation of a New Dermal Cryotherapy System for the Treatment of Benign Pigmented Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R2 Dermatology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>R2 Dermatology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the ability of the Dermal Cooling System to reduce pigmentation in benign
      pigmented lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, non-randomized, multi-center study of the Dermal Cooling System
      to verify that the device causes a reduction in pigmentation in benign pigmented lesions, and
      to determine at what parameters the device is most effective.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of pigmentation in treated lesions</measure>
    <time_frame>90 days</time_frame>
    <description>Changes in pigmentation graded using a 4-point standardized scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of device- or procedure-related adverse events</measure>
    <time_frame>0 to 12 months</time_frame>
    <description>Side effects, discomfort assessments both during treatment and follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Pigmented Skin Lesion</condition>
  <arm_group>
    <arm_group_label>Treatment with cryotherapy device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To include subjects with one or more benign pigmented lesions who are willing to have the pigmented skin exposed to cooling with the Dermal Cooling System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dermal Cooling System</intervention_name>
    <description>Dermal cryotherapy</description>
    <arm_group_label>Treatment with cryotherapy device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects &gt; 18 years of age.

          2. Subject has one or more benign pigmented lesions (e.g., solar lentigines, melasma,
             freckles, caf√© au lait, nevi, or hyperpigmentation), in an area suitable for treatment

          3. Subject is willing to have up to 40 treatment sites and/or an area up to 8 square
             inches treated depending on the size and nature of the lesions identified.

          4. Subject is willing to have digital photographs taken of the treatment area and agrees
             to use of photographs for presentation, educational, or marketing purposes.

          5. Subject is willing to cover treated area or have very limited sun exposure and use an
             approved sunscreen of SPF 50 or higher on the treated areas for the duration of the
             study, including the follow-up period, if requested.

          6. Subject has read and signed a written informed consent form.

        Exclusion Criteria:

          1. Physician prescribed medical or surgical treatment, or use of over-the-counter
             products to alter skin color, in the area of intended treatment in the previous 6
             months (e.g., hydroquinone, corticosteroids, laser surgery)

          2. Artificial tanning in the area of intended treatment within 1 month (e.g., spray,
             lotion, tanning bed) or intention to use artificial tanning within the follow-up
             period

          3. Scars or tattoos in the location of the treatment sites

          4. History of vitiligo, eczema, or psoriasis in the area of treatment

          5. History of melanoma

          6. Known history of illness or adverse reaction to cold insult (e.g., cryoglobulinemia,
             cold urticaria, paroxysmal cold hemoglobinuria, Reynaud's disease.

          7. History of abnormal wound healing or abnormal scarring

          8. Inability or unwillingness to comply with the study requirements.

          9. Current enrollment in a clinical study of any other unapproved investigational drug or
             device.

         10. Any other condition or laboratory value that would, in the professional opinion of the
             investigator, potentially affect response or participation in this clinical study, or
             would pose an unacceptable risk to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristine Tatsutani, PhD</last_name>
    <role>Study Director</role>
    <affiliation>R2 Dermatology, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristine Tatsutani, PhD</last_name>
    <phone>1-844-372-3376</phone>
    <email>ktatsutani@r2derm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dennell Vargas</last_name>
    <phone>925-378-4416</phone>
    <email>dvargas@r2derm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlette Vargas</last_name>
      <phone>925-930-7267</phone>
      <email>cvargas@diabloclinical.com</email>
    </contact>
    <investigator>
      <last_name>Leonard Chuck, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arbutus Laser Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6J 1Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Wasilenchuk</last_name>
      <phone>604-731-5512</phone>
      <email>jen@arbutuslaser.com</email>
    </contact>
    <investigator>
      <last_name>Gerald Boey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pigmentation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

